

Ligand Pharmaceuticals Inc (LGND) - Financial and Strategic SWOT Analysis Review

https://marketpublishers.com/r/L3231C97549EN.html

Date: May 2021 Pages: 68 Price: US\$ 125.00 (Single User License) ID: L3231C97549EN

Abstracts

Ligand Pharmaceuticals Inc (LGND) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company's businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company's key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

Business description – A detailed description of the company's operations and business divisions.

Corporate strategy – Analyst's summarization of the company's business strategy.

SWOT Analysis – A detailed analysis of the company's strengths, weakness, opportunities and threats.

Company history – Progression of key events associated with the company.

Major products and services – A list of major products, services and brands of the company.

Key competitors – A list of key competitors to the company.



Key employees – A list of the key executives of the company.

Executive biographies – A brief summary of the executives' employment history.

Key operational heads – A list of personnel heading key departments/functions.

Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.

Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.

Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Ligand Pharmaceuticals Inc (Ligand) develops and acquires technologies that help biopharmaceutical companies in the discovery and development of medicines. Its major research technologies include formulation science, structure-based drug design, antibody discovery technologies and liver targeted pro-drug technologies, which assist pharmaceutical companies in securing prescription drug approvals. Its technologies and research capabilities contributed the development of a diversified portfolio of biotechnology and pharmaceutical products for inflammatory, respiratory central nervous system, oncology, ophthalmology, haematology, musculoskeletal disorder, osteoporosis, and among others. Ligand also offers late-stage development, regulatory management and commercialization support in partnership with other pharmaceutical companies. Ligand is headquartered in San Diego, California, the US.

Ligand Pharmaceuticals Inc Key Recent Developments

May 03,2021: Ligand Reports First Quarter 2021 Financial Results Feb 03,2021: Ligand Reports Fourth Quarter and Full Year 2020 Financial Results Jan 20,2021: Ligand's Q4 financial results to reported February 2021 Oct 30,2020: Ligand reports third quarter 2020 financial results



Aug 11,2020: Ligand Pharmaceuticals agrees to acquire Pfenex for \$516m

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.

The profile analyzes the company's business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors' business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.

The company's core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.

Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies' strategic, financial and operational performance.

Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.



Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company



Contents

SECTION 1 - ABOUT THE COMPANY

Ligand Pharmaceuticals Inc - Key Facts Ligand Pharmaceuticals Inc - Key Employees Ligand Pharmaceuticals Inc - Key Employee Biographies Ligand Pharmaceuticals Inc - Major Products and Services Ligand Pharmaceuticals Inc - History Ligand Pharmaceuticals Inc - Company Statement Ligand Pharmaceuticals Inc - Locations And Subsidiaries Head Office Other Locations & Subsidiaries

SECTION 2 – COMPANY ANALYSIS

Company Overview Ligand Pharmaceuticals Inc - Business Description **Business Segment: Captisol Sales** Performance **Business Segment: Contract Revenue** Performance **Business Segment: Royalties** Performance **R&D** Overview Ligand Pharmaceuticals Inc - Corporate Strategy Ligand Pharmaceuticals Inc - SWOT Analysis SWOT Analysis - Overview Ligand Pharmaceuticals Inc - Strengths Ligand Pharmaceuticals Inc - Weaknesses Ligand Pharmaceuticals Inc - Opportunities Ligand Pharmaceuticals Inc - Threats Ligand Pharmaceuticals Inc - Key Competitors

SECTION 3 – COMPANY FINANCIAL RATIOS

Financial Ratios - Capital Market Ratios Financial Ratios - Annual Ratios Performance Chart

Ligand Pharmaceuticals Inc (LGND) - Financial and Strategic SWOT Analysis Review



Financial Performance Financial Ratios - Interim Ratios Financial Ratios - Ratio Charts

SECTION 4 – COMPANY'S LIFESCIENCES FINANCIAL DEALS AND ALLIANCES

Ligand Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021 Ligand Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Type, 2015 to YTD 2021 Ligand Pharmaceuticals Inc, Recent Deals Summary

SECTION 5 - COMPANY'S RECENT DEVELOPMENTS

May 03, 2021: Ligand Reports First Quarter 2021 Financial Results Feb 03, 2021: Ligand Reports Fourth Quarter and Full Year 2020 Financial Results Jan 20, 2021: Ligand's Q4 financial results to reported February 2021 Oct 30, 2020: Ligand reports third quarter 2020 financial results Aug 11, 2020: Ligand Pharmaceuticals agrees to acquire Pfenex for \$516m Aug 03, 2020: Ligand reports second quarter 2020 financial results May 06, 2020: Ligand reports first quarter 2020 financial results Apr 06, 2020: Ligand provides a corporate update and announces May 6th as the date for first quarter earnings call Mar 10, 2020: Ligand's presentation at the Barclays Global Healthcare Conference now a webcast only, new slides available on Ligand.com Feb 27, 2020: Ligand raises 2020 financial guidance due to higher captisol material sales

SECTION 6 – APPENDIX

Methodology Ratio Definitions About GlobalData Contact Us Disclaimer



List Of Tables

LIST OF TABLES

Ligand Pharmaceuticals Inc, Key Facts Ligand Pharmaceuticals Inc, Key Employees Ligand Pharmaceuticals Inc, Key Employee Biographies Ligand Pharmaceuticals Inc, Major Products and Services Ligand Pharmaceuticals Inc, History Ligand Pharmaceuticals Inc, Other Locations Ligand Pharmaceuticals Inc, Subsidiaries Ligand Pharmaceuticals Inc, Key Competitors Ligand Pharmaceuticals Inc, Ratios based on current share price Ligand Pharmaceuticals Inc, Annual Ratios Ligand Pharmaceuticals Inc, Annual Ratios (Cont...1) Ligand Pharmaceuticals Inc, Annual Ratios (Cont...2) Ligand Pharmaceuticals Inc, Interim Ratios Ligand Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021 Ligand Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Type, 2015 to YTD 2021 Ligand Pharmaceuticals Inc, Recent Deals Summary **Currency Codes Capital Market Ratios** Equity Ratios **Profitability Ratios** Cost Ratios Liquidity Ratios Leverage Ratios

Efficiency Ratios



List Of Figures

LIST OF FIGURES

Ligand Pharmaceuticals Inc, Performance Chart (2016 - 2020) Ligand Pharmaceuticals Inc, Ratio Charts Ligand Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021 Ligand Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2015 to YTD 2021



I would like to order

Product name: Ligand Pharmaceuticals Inc (LGND) - Financial and Strategic SWOT Analysis Review Product link: <u>https://marketpublishers.com/r/L3231C97549EN.html</u>

Price: US\$ 125.00 (Single User License / Electronic Delivery) If you want to order Corporate License or Hard Copy, please, contact our Customer Service: <u>info@marketpublishers.com</u>

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <u>https://marketpublishers.com/r/L3231C97549EN.html</u>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name: Last name: Email: Company: Address: City: Zip code: Country: Tel: Fax: Your message:

**All fields are required

Custumer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <u>https://marketpublishers.com/docs/terms.html</u>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970